Headache News and Research

Latest Headache News and Research

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease.

17 Dec 2013

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Scientists find vaccine that blocks invasion of blood cell by Malaria parasite

Scientists from Singapore's Nanyang Technological University (NTU) have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.

16 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

NTU researchers find way to block invasion of Malaria parasite in blood cells

Scientists from Singapore's Nanyang Technological University have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.

16 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Researchers develop first test to identify acute mountain sickness

The first test to identify acute mountain sickness has been developed by a team of researchers in Italy and France and is presented today at EuroEcho-Imaging 2013. The test could revolutionise trekking and climbing by predicting who will develop the potentially deadly condition so they can avoid high altitudes, ascend more gradually or take preventative medication.

12 Dec 2013

Special treatment? Examining who on Capitol Hill has to get coverage on the health law's exchanges

News outlets take a closer look at the circumstances around how members of Congress and their staffs are navigating getting health coverage on the DC insurance exchange -- and just who is required to do so and by when.

12 Dec 2013

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.

12 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Oregon Gov. Kitzhaber to seek 4th term; health care will likely be a campaign issue

John Kitzhaber announced he intends to seek an unprecedented fourth term. In the background, his state continues to experience difficulties with Cover Oregon, the state's online insurance marketplace.

11 Dec 2013

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Indulgences abound during the holidays—from family gatherings to parties with friends and even stockings stuffed with goodies from Santa. For children with diabetes, overindulging on the delicacies of the season could result in more than a stomach ache, it could mean a trip to the emergency room.

10 Dec 2013

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

electroCore’s non invasive vagus nerve stimulation therapy for the prevention and treatment of cluster headache and migraine was reviewed at both the AHS Annual Scottsdale Headache Symposium (Nov 21st to 24th) and the NANS meeting this weekend (Dec 5th to 8th).

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Repetitive transcranial magnetic stimulation uses a non-invasive and relatively painless tool to stimulate the human brain in vivo using very strong, pulsed magnetic fields. It is also used to explore and elucidate neocortical functions and treat neuropsychiatric disorders.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

College students not only bring dirty socks but also mononucleosis to home

One of the hallmarks of heading home for winter break is the enormous amounts of laundry college students bring as a welcome home present for Mom and Dad. But the dirty socks might not be the only unwelcome guest they transport home. They might also bring mononucleosis, better known as mono.

6 Dec 2013

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

Headache News and Research

Latest Headache News and Research

Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Scientists find vaccine that blocks invasion of blood cell by Malaria parasite

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

NTU researchers find way to block invasion of Malaria parasite in blood cells

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Researchers develop first test to identify acute mountain sickness

Special treatment? Examining who on Capitol Hill has to get coverage on the health law's exchanges

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Oregon Gov. Kitzhaber to seek 4th term; health care will likely be a campaign issue

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

electroCore’s non-invasive VNS therapy for headaches reviewed at AHS and NANS meetings

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

College students not only bring dirty socks but also mononucleosis to home

EMA expands administration options for Hizentra

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in